Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Uloženo v:
Hlavní autoři: | , , , , , , , , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | angličtina |
Vydáno: |
Philipps-Universität Marburg
2023
|
Témata: | |
On-line přístup: | Plný text ve formátu PDF |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
No abstracts were found for this record.